Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
89.65 ^USD	+2.66%		-0.39%	+132.25%

11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE
11-06	Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q3 Revenue $4.7M, vs. FactSet Est of $3.8M	MT

Analyst Reco.

Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating	10-28	MT
Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating	10-28	MT
Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	10-27	MT
Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, WSJ Reports	10-10	MT
Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says	10-08	MT
J&J's experimental psoriasis drug shows promise against Bristol's treatment	09-17	RE
Barclays Initiates Protagonist Therapeutics at Overweight	09-17	MT
Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target	09-12	MT
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	06-17	MT
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	03-11	MT
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	03-10	MT
Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target	12-06	MT
Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target	11-05	MT
TD Cowen Initiates Protagonist Therapeutics at Buy	24-09-24	MT
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target	24-09-09	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating	24-07-25	MT
BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating	24-07-24	MT
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing	24-06-11	MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing	24-06-11	MT
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	24-04-03	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	24-02-28	MT
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target	23-10-30	MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating	23-09-25	MT
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating	23-07-06	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $28 From $31, Maintains Market Outperform Rating	23-03-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Analyst Reco.

Filters